Design Therapeutics (DSGN) Preferred Stock Liabilities (2020)
Design Therapeutics (DSGN) posted quarterly Preferred Stock Liabilities of $45.4 million for Q4 2020, little changed on a QoQ basis from $45.4 million in Q3 2020.
Powered by 
Analysis
Design Therapeutics (DSGN) Preferred Stock Liabilities (2020) Analysis & Trends
Design Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $45.4 million in Q4 2020.
- Preferred Stock Liabilities for Q4 2020 came in at $45.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $45.4 million (changed N/A YoY), and the FY2020 annual result was $45.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $45.4 million in Q4 2020, from $45.4 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $45.4 million in Q1 2020 and troughed at $45.4 million in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 45.36 Mn |
| Sep 30, 2020 | 45.36 Mn |
| Jun 30, 2020 | 45.36 Mn |
| Mar 31, 2020 | 45.36 Mn |